Remove 2026 Remove Compounding Remove Insurance
article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

A qualifying medication is prescribed by their healthcare provider The patients who have no insurance or have Medicare Part D Patients who are not enrolled in Medicaid, full Low-Income Subsidy, or Veterans (VA) benefits. The patient must-have commercial health insurance to use the savings card. Virgin Islands.

article thumbnail

Connected customer data: a golden opportunity for pharma marketers

pharmaphorum

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. Better customer experience.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.

article thumbnail

Turning Reconciliation into a Revenue Growth Engine

Drug Topics

For instance, the MFP is expected to affect approximately 10 drugs in 2026, with the list expanding annually, potentially creating a $22,000 monthly financial impact for average retail pharmacies.

article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

1 For these reasons, the authors conducted this study to evaluate the clinical success and patient outcomes following the mandatory conversion from Humira to a biosimilar because of insurance-related restrictions.